Adult Vaccination Coverage, National Immunization Survey—Adult, 2007

Learning Objectives for this Presentation:
After the presentation participants will be able to describe adult vaccination coverage levels and reasons for nonvaccination.

Background:
Coverage levels are needed for newly licensed vaccines Tdap, zoster and HPV. Current levels will be useful for several established vaccines—influenza and tetanus.

Objectives:
To estimate 2007 coverage levels of influenza, PPV, tetanus/Tdap, HepA, HPV and zoster vaccines among adults.
To measure current reasons for nonvaccination and other vaccination-related knowledge and practices among U.S. adults.

Methods:
A national telephone survey was conducted May-September 2007 of a representative sample (n=7,055) of adults aged ≥18 years to measure coverage and reasons for nonvaccination for the following routine vaccines: influenza; PPV; tetanus/Tdap; hepatitis A; HPV; and zoster. Telephone numbers were used from two sources: race/ethnic-specific from the National Health Interview Survey and age-targeted from Survey Sampling International.

Results:
Influenza vaccination coverage levels for the 2006-07 influenza season were 37% among 18-49 year-olds at high-risk (HR) for influenza-related complications; 42% among 50-64 year-olds; and 69% among adults aged 65+ years. Pneumococcal vaccination levels were 30% among HR18-64 year-olds and 66% among adults aged 65+ years. Levels of tetanus vaccination within the past 10 years were 57% for 18-49 year-olds, 57% for 50-64 year-olds and 44% for 65+ year-olds. Tdap vaccination coverage was 2% among 18-64 year-olds and of those receiving tetanus vaccination in the past 2 years, 21% received Tdap. Zoster vaccination coverage was 2% among 60+ year-olds and 0.8% among 50-59 year-olds. Two-plus HepA levels were 12% among 18-49 year-olds. One-plus HPV levels were 10% among females 18-26 years of age and 1% among females aged 27-49 years.

Conclusions:
Adult vaccination rates for established vaccines remain relatively low and additional efforts are needed to significantly boost coverage. Early uptake levels of newer vaccines were as anticipated. Rapid improvement is projected as people learn more about these vaccines.